BioMarin Pharmaceutical's total inventories for the quarter that ended in Mar. 2026 was MXN22,960 Mil. BioMarin Pharmaceutical's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was MXN23,173 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. BioMarin Pharmaceutical's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was MXN108.05.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
BioMarin Pharmaceutical's Days Inventory for the
three
months ended in Mar. 2026 was 601.35.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioMarin Pharmaceutical's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.15.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioMarin Pharmaceutical's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 1.68.
BioMarin Pharmaceutical (MEX:BMRN) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
BioMarin Pharmaceutical's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioMarin Pharmaceutical's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
BioMarin Pharmaceutical Total Inventories Related Terms
BioMarin Pharmaceutical Total Inventories Historical Data
* Premium members only.
The historical data trend for BioMarin Pharmaceutical's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of MXN22,960 Mil mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Total Inventories of MXN22,960 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Total Inventories too high?
BioMarin Pharmaceutical's current Total Inventories is MXN22,960 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Total Inventories compare to ARWR and MDGL?
BioMarin Pharmaceutical's Total Inventories of MXN22,960 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Total Inventories is MXN22,960 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,417.45, compared to a current price of MXN959.00 — trading 32.3% below its estimated fair value. The current Total Inventories is MXN22,960 Mil. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Total Inventories is MXN22,960 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of MXN959.00 is trading 32.3% below its estimated GF Value™ of MXN1,417.45.
GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.
Key valuation signals for MEX:BMRN:
Total Inventories: MXN22,960 Mil
GF Value™: MXN1,417.45 vs. price of MXN959.00 (32.3% below fair value)
No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score
Get the complete analysis for MEX:BMRN
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BMRN has been successfully added to your 
